临床试验Nct页
Clinical Trial Results:
A multi-centre, double-blind, parallel-group, randomised, placebo-controlled study to investigate the safety and tolerability of 0.25, 0.5 and 1.0 mg NS 2330 orally and once daily during a 14-week treatment period as add-on to 10 mg donepezil once daily in patients with mild to moderate dementia of the Alzheimer's type.
| Summary | |
EudraCT number | 2004-001100-12 |
Trial protocol | CZ HU SK |
Global completion date | 18 Mar 2005 |
| Paediatric regulatory details | |
Is the trial part of an agreed EMA paediatric investigation plan? | No |
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? | No |
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? | No |
| Results information | |
Results version number | v1(current) |
This version publication date | 30 Sep 2018 |
First version publication date | 30 Sep 2018 |
Other versions | |
Summary report(s) | Statement |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03 for further information.